United States — Food and Drug Administration & United States — Medicare

United States — Food and Drug Administration: The United States — Food and Drug Administration has cleared the CareMiBrain system for use and has approved new monoclonal antibody treatments for Alzheimer's Disease, creating a market for the PET scans.

United States — Medicare: United States — Medicare covers brain PET scans for beta-amyloid plaque detection and new monoclonal antibody treatments for Alzheimer's Disease, which is crucial for patient access to Grey Matters Health Inc.'s services.